Dr. Paul Kil

Uitgebreid CV

Werkervaring

2020 – heden Medisch Directeur en Uroloog bij Andros Clinics
1991 – 2020 Uroloog bij Elisabeth-Tweesteden Ziekenhuis (ETZ), Tilburg
1989 – 1990 Opleiding Urologie, Groot Ziekengasthuis, ‘s-Hertogenbosch
1987 – 1988 Opleiding Urologie, Radboud universitair medisch centrum, Nijmegen
1984 – 1986 Opleiding Chirurgie, Stichting Deventer ziekenhuizen, Deventer
1980 – 1983 Wetenschappelijk medewerker, Fysiologisch Instituut, Rijksuniversiteit Utrecht

Overige functies

Voorzitter Stichting Dutchstone, Stichting ten behoeve van diagnostiek en behandeling van patiënten met urologische problemen in ontwikkelingslanden en opleiding artsen en verpleegkundigen.

2020-heden Medisch Directeur Diagnovum, Tilburg
2011-heden Lid beroepsgenoot Centraal Tuchtcollege voor de Gezondheidszorg

Opleiding

Promotie Rijksuniversiteit Utrecht
‘Left ventricular filling: influence on cardiac performance and inotropic state’
Studie geneeskunde, Rijksuniversiteit Utrecht
Studie Geneeskunde, Exchange Program Netherlands Institute for Educational Exchange Gustavus Aldolphus College, Saint Peter Minnesota, USA

Lidmaatschappen

Nederlandse Vereniging voor Urologie (NVU)
American Urological Association (corresponding member)
European Association of Urology (EBU-fellow)

Wetenschappelijke publicaties

Hieronder vindt u een selectie van publicaties, bekijk hier alle publicaties

Differences in treatment choices between prostate cancer patients using a decision aid and patients receiving care as usual: results from a randomized controlled trial.
Lamers RED, Cuypers M, de Vries M, van de Poll-Franse LV, Bosch JLHR, Kil PJM.World J Urol. 2021 Dec;39(12):4327-4333. doi: 10.1007/s00345-021-03782-7. Epub 2021 Jul 17.PMID: 3427297

A clinician’s guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer.
Veen KM, de Angst IB, Mokhles MM, Westgeest HM, Kuppen M, Groot CAU, Gerritsen WR, Kil PJM, Takkenberg JJM.J Cancer Res Clin Oncol. 2020 Aug;146(8):2067-2075. doi: 10.1007/s00432-020-03286-8. Epub 2020 Jun 17.PMID: 32556680

Treatment Preferences of Patients With Benign Prostatic Hyperplasia Before and After Using a Web-based Decision Aid.
Lamers RED, van der Wijden FC, de Angst IB, de Vries M, Cuypers M, van Melick HHE, de Beij JS, Oerlemans DJAJ, van de Beek K, Bosch RJLHR, Kil PJM.Urology. 2020 Mar;137:138-145. doi: 10.1016/j.urology.2019.12.026. Epub 2019 Dec 30.PMID: 31899227

Phytotherapy Adds to the Therapeutic Armamentarium for the Treatment of Mild-To-Moderate Lower Urinary Tract Symptoms in Men.
Fornara P, Madersbacher S, Vahlensieck W, Bracher F, Romics I, Kil P.Urol Int. 2020;104(5-6):333-342. doi: 10.1159/000504611. Epub 2019 Dec 18.PMID: 31852006

Changes in internet use and wishes of cancer survivors: A comparison between 2005 and 2017.
van Eenbergen MCHJ, Vromans RD, Boll D, Kil PJM, Vos CM, Krahmer EJ, Mols F, van de Poll-Franse LV.Cancer. 2020 Jan 15;126(2):408-415. doi: 10.1002/cncr.32524. Epub 2019 Oct 3.PMID: 31580497

Development and usability testing of a multi-criteria value clarification methods for patients with localized prostate cancer.
de Angst IB, Weernink MG, Kil PJ, van Til JA, Cornel EB, Takkenberg JJ.Health Informatics J. 2020 Mar;26(1):486-498. doi: 10.1177/1460458219832055. Epub 2019 Mar 27.PMID: 30915900

Should we involve patients more actively? Perspectives of the multidisciplinary team on shared decision-making for older patients with metastatic castration-resistant prostate cancer.
de Angst IB, Kil PJM, Bangma CH, Takkenberg JJM.J Geriatr Oncol. 2019 Jul;10(4):653-658. doi: 10.1016/j.jgo.2018.12.003. Epub 2019 Jan 11.PMID: 30639265

Effectiveness of a web-based treatment decision aid for men with lower urinary tract symptoms due to benign prostatic hyperplasia.
van der Wijden FC, de Angst IB, Lamers RED, Cuypers M, de Vries M, van Melick HHE, de Beij JS, Oerlemans DJAJ, van de Beek K, Kil PJM.BJU Int. 2019 Jul;124(1):124-133. doi: 10.1111/bju.14646. Epub 2019 Mar 4.PMID: 30589205

Longitudinal regret and information satisfaction after deciding on treatment for localized prostate cancer with or without a decision aid. Results at one-year follow-up in the PCPCC trial.
Cuypers M, Lamers RED, Kil PJM, van de Poll-Franse LV, de Vries M.Patient Educ Couns. 2019 Mar;102(3):424-428. doi: 10.1016/j.pec.2018.10.006. Epub 2018 Oct 4.PMID: 30314830

Uptake and usage of an online prostate cancer treatment decision aid in Dutch clinical practice: A quantitative analysis from the Prostate Cancer Patient Centered Care trial.
Cuypers M, Lamers RE, Kil PJ, van Tol-Geerdink JJ, van Uden-Kraan CF, van de Poll-Franse LV, de Vries M.Health Informatics J. 2019 Dec;25(4):1498-1510. doi: 10.1177/1460458218779110. Epub 2018 Jun 1.PMID: 29857789

Impact of a web-based prostate cancer treatment decision aid on patient-reported decision process parameters: results from the Prostate Cancer Patient Centered Care trial.
Cuypers M, Lamers RED, Kil PJM, van de Poll-Franse LV, de Vries M.Support Care Cancer. 2018 Nov;26(11):3739-3748. doi: 10.1007/s00520-018-4236-8. Epub 2018 May 12.PMID: 29752528

The impact of prostate cancer diagnosis and treatment decision-making on health-related quality of life before treatment onset.
Cuypers M, Lamers RED, Cornel EB, van de Poll-Franse LV, de Vries M, Kil PJM.Support Care Cancer. 2018 Apr;26(4):1297-1304. doi: 10.1007/s00520-017-3953-8. Epub 2017 Nov 10.PMID: 29127529

A global, incremental development method for a web-based prostate cancer treatment decision aid and usability testing in a Dutch clinical setting.
Cuypers M, Lamers RE, Kil PJ, The R, Karssen K, van de Poll-Franse LV, de Vries M.Health Informatics J. 2019 Sep;25(3):701-714. doi: 10.1177/1460458217720393. Epub 2017 Jul 27.PMID: 28747076

How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer.
Lamers RE, Cuypers M, de Vries M, van de Poll-Franse LV, Ruud Bosch JL, Kil PJ.Urol Oncol. 2017 Feb;35(2):37.e9-37.e17. doi: 10.1016/j.urolonc.2016.09.007. Epub 2016 Oct 27.PMID: 28341494

Cancer survivors’ preference for follow-up care providers: a cross-sectional study from the population-based PROFILES-registry.
Huibertse LJ, van Eenbergen M, de Rooij BH, Bastiaens MT, Fossion LM, de la Fuente RB, Kil PJ, Koldewijn EL, Meier AH, Mommers RJ, Niemer AQ, Oddens JR, Oomens EH, Prins M, de Roos KP, Thissen MR, Timmermans MW, Wijsman BP, van de Poll-Franse LV, Ezendam NP.Acta Oncol. 2017 Feb;56(2):278-287. doi: 10.1080/0284186X.2016.1267398. Epub 2017 Jan 9.PMID: 28068157

Prostate cancer survivors with a passive role preference in treatment decision-making are less satisfied with information received: Results from the PROFILES registry.
Cuypers M, Lamers RED, de Vries M, Husson O, Kil PJM, van de Poll-Franse LV.Urol Oncol. 2016 Nov;34(11):482.e11-482.e18. doi: 10.1016/j.urolonc.2016.06.015. Epub 2016 Jul 16.PMID: 27432432

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA.Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20.PMID: 27108162

Development of a decision aid for the treatment of benign prostatic hyperplasia: A four stage method using a Delphi consensus study.
Lamers RED, Cuypers M, Garvelink MM, de Vries M, Bosch JLHR, Kil PJM.Patient Educ Couns. 2016 Jul;99(7):1249-1256. doi: 10.1016/j.pec.2016.02.004. Epub 2016 Feb 8.PMID: 26899631

Presence and Number of Positive Surgical Margins after Radical Prostatectomy for Prostate Cancer: Effect on Oncological Outcome in a Population-Based Cohort.
Richters A, Derks J, Fossion LM, Kil PJ, Verhoeven RH, Aarts MJ.Urol Int. 2015;95(4):472-7. doi: 10.1159/000441012. Epub 2015 Nov 3.PMID: 26523366